Table 3 Clinicopathological characteristics and univariate analysis of 122 cases of PTMC patients who underwent prophylactic CLND

Gender (M/F)

60/62

44/16

16/46

0.015^a

Age ± SD (years)

48 ± 11

46 ± 10

50 ± 11

0.044^a,b

≥45/<45

83/39

37/23

46/16

0.138

≥50/<50

57/65

21/39

36/26

0.011^a

Tumor size ± SD (mm)

6.5 ± 2.6

7.2 ± 2.3

5.8 ± 2.7

0.002^a,b

≥5/<5

95/27

51/9

44/18

0.062

≥7/<7

59/63

36/24

23/39

0.011^a

Multifocality (%)

19 (15.6)

14 (23.3)

5 (8.1)

0.020^a

ETE (%)

7 (5.7)

5 (8.3)

2 (3.2)

0.269^c

T stage (T1/2:T3/4)

115/7

55/5

60/2

0.269^c

With HT (%)

43 (35.2)

19 (31.7)

24 (38.7)

0.416

Bilateral PTMC (%)

60 (50.8)

26 (61.9)

34 (42.5)

0.042^a

Preoperative tumor size (mm)

6.8 ± 2.8

7.5 ± 2.6

6.1 ± 2.9

0.008^a

≥5/<5

99/23

52/8

47/15

0.125

≥7/<7

61/61

37/23

24/38

0.001^a

Preoperative multifocality (%)

16(13.1)

12(20.0)

4(6.6)

0.027^a